| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3843807 | Actas Urológicas Españolas | 2011 | 4 Pages |
Abstract
despite the limits of this experience, we can say that Sunitinib appears to be an active and safe option in patients with hormone-refractory prostate cancer that is resistant to chemotherapy with Docetaxel.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
J.M. Gasent, E. Grande, J. Casinello, M. Provencio, J.B. Laforga, V. Alberola,